Neurobiological studies of dementia - Biological markers and neuroprotective strategies for Alzheimer disease

Acta Neurologica Taiwanica

Volumn 15, Issue 1, 2006, Pages 68-71

  Tanaka, Toshihisa ^a   Isoe Wada, Kenji ^b   Yamamori, Hidenaga ^c   Kato, Kiyoko ^a   Nessa, Begum Nurun ^a   Sadik, Golam Md ^a   Takeda, Masatoshi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Alzheimer's disease; Biomarker; Dementia; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; LITHIUM CHLORIDE; TAU PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

ALZHEIMER DISEASE; CONFERENCE PAPER; CYTOTOXICITY; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DRUG TARGETING; HUMAN; NEUROBIOLOGY; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; HUMANS; PHOSPHORYLATION; TAU PROTEINS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 33645668949     PISSN: 10196099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828-34.
2. Urakami K, Wada K, Arai H, et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci 2001;183:95-8.
3. Green AJ, Harvey RJ, Thompson EJ, et al. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett 1999;259:133-5.
4. Otto M, Wiltfang J, Tumani H, et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997;225:210-2.
5. Kudo T, Mima T, Hashimoto R, et al. Tau protein is a potential biological marker for normal pressure hydrocephalus. Psychiatry Clin Neurosci 2000;54:199-202.
6. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.
7. Hampel H, Buerger K, Kohnken R, et al. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol 2001;49:545-6.
8. Ishiguro K, Ohno H, Arai H, et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999;270:91-4.
9. Itoh N, Arai H, Urakami K, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 2001;50:150-6.
10. Hu YY, He SS, Wang X, et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Patol 2002;160:1269-78.
11. Paradis E, Douillard H, Koutroumanis M, et al. Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons. J Neurosci 1996;16:7533-59.
12. Yamamori H, Tanaka T, Kudo T, et al. Amyloid-β down-regulates XIAP expression in human SH-SY5Y neuroblastoma cells. NeuroReport 2004;15;851-4.